HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Coherus BioSciences (NASDAQ:CHRS) and maintained a $12 price target.
May 24, 2024 | 10:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Coherus BioSciences and maintained a $12 price target.
The reiteration of a Buy rating and the maintenance of a $12 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100